First Header Logo Second Header Logo

Connection

Herbert Bonkovsky to Ribavirin

Back to Details
This is a "connection" page, showing publications Herbert Bonkovsky has written about Ribavirin.
Herbert Bonkovsky
Connection Strength
2.242
Ribavirin
  1. Bonkovsky HL, Tice AD, Yapp RG, Bodenheimer HC, Monto A, Rossi SJ, Sulkowski MS. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol. 2008 Nov; 103(11):2757-65.
    View in: PubMed
    Score: 0.332
  2. Bonkovsky HL, Salek J. No role of the -2518 promoter polymorphism of monocyte chemotactic protein-1 in chronic hepatitis C. Gastroenterology. 2005 Oct; 129(4):1361-2.
    View in: PubMed
    Score: 0.273
  3. Bonkovsky HL, Stefancyk D, McNeal K, Banner BF, Liu Q, Zucker GM, Israel J, Stagias J, Colker J. Comparative effects of different doses of ribavirin plus interferon-alpha2b for therapy of chronic hepatitis C: results of a controlled, randomized trial. Dig Dis Sci. 2001 Oct; 46(10):2051-9.
    View in: PubMed
    Score: 0.207
  4. Szabo G, Katz E, Bonkovsky HL. Management of recurrent hepatitis C after liver transplantation: a concise review. Am J Gastroenterol. 2000 Sep; 95(9):2164-70.
    View in: PubMed
    Score: 0.192
  5. O'Bryan JM, Potts JA, Bonkovsky HL, Mathew A, Rothman AL. Extended interferon-alpha therapy accelerates telomere length loss in human peripheral blood T lymphocytes. PLoS One. 2011; 6(8):e20922.
    View in: PubMed
    Score: 0.102
  6. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010 Sep; 52(3):833-44.
    View in: PubMed
    Score: 0.096
  7. Rustgi VK, Lee WM, Lawitz E, Gordon SC, Afdhal N, Poordad F, Bonkovsky HL, Bengtsson L, Chandorkar G, Harding M, McNair L, Aalyson M, Alam J, Kauffman R, Gharakhanian S, McHutchison JG. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Hepatology. 2009 Dec; 50(6):1719-26.
    View in: PubMed
    Score: 0.091
  8. Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology. 2009 Dec; 137(6):1986-94.
    View in: PubMed
    Score: 0.090
  9. Lok AS, Everhart JE, Chung RT, Kim HY, Everson GT, Hoefs JC, Greenson JK, Sterling RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology. 2009 Jun; 49(6):1828-37.
    View in: PubMed
    Score: 0.088
  10. Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, O'Brien TR. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2009 Jun; 49(6):1847-58.
    View in: PubMed
    Score: 0.088
  11. Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok AS, Su GL. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol. 2009 Feb; 7(2):219-26.
    View in: PubMed
    Score: 0.084
  12. Sjogren MH, Sjogren R, Lyons MF, Ryan M, Santoro J, Smith C, Reddy KR, Bonkovsky H, Huntley B, Faris-Young S. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Dig Dis Sci. 2007 Jun; 52(6):1540-7.
    View in: PubMed
    Score: 0.076
  13. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology. 2006 Dec; 44(6):1675-84.
    View in: PubMed
    Score: 0.074
  14. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, Kulig CC, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, Gretch DR. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007 Mar; 46(3):420-31.
    View in: PubMed
    Score: 0.074
  15. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007 Jan; 132(1):103-12.
    View in: PubMed
    Score: 0.074
  16. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004 Apr; 126(4):1015-23; discussion 947.
    View in: PubMed
    Score: 0.061
  17. Bonkovsky HL, Woolley JM. Outcomes research in chronic viral hepatitis C: effects of interferon therapy. Can J Gastroenterol. 2000 Jul-Aug; 14 Suppl B:21B-29B.
    View in: PubMed
    Score: 0.047
  18. Fontana RJ, Litman HJ, Dienstag JL, Bonkovsky HL, Su G, Sterling RK, Lok AS. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver Int. 2012 Apr; 32(4):665-74.
    View in: PubMed
    Score: 0.026
  19. O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, Shao Y, Shiffman ML, Dotrang M, Sninsky JJ, Bonkovsky HL, Pfeiffer RM. An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One. 2011; 6(7):e20904.
    View in: PubMed
    Score: 0.025
  20. Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011 Apr; 53(4):1100-8.
    View in: PubMed
    Score: 0.025
  21. Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut. 2010 Oct; 59(10):1401-9.
    View in: PubMed
    Score: 0.024
  22. Morgan TR, Lambrecht RW, Bonkovsky HL, Chung RT, Naishadham D, Sterling RK, Fontana RJ, Lee WM, Ghany MG, Wright EC, O'Brien TR. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol. 2008 Oct; 49(4):548-56.
    View in: PubMed
    Score: 0.021
  23. Lindsay KL, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson GT, Lok AS, Bonkovsky HL, Lee WM, Morgan TR, Ghany MG. Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol. 2008 Feb; 6(2):234-41.
    View in: PubMed
    Score: 0.020
  24. Lok AS, Everhart JE, Chung RT, Padmanabhan L, Greenson JK, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Ghany MG, Morishima C. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol. 2007 Feb; 5(2):245-54.
    View in: PubMed
    Score: 0.019
  25. Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Gretch DR. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology. 2006 Aug; 44(2):360-7.
    View in: PubMed
    Score: 0.018
  26. Morishima C, Polyak SJ, Ray R, Doherty MC, Di Bisceglie AM, Malet PF, Bonkovsky HL, Sullivan DG, Gretch DR, Rothman AL, Koziel MJ, Lindsay KL. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis. 2006 Apr 01; 193(7):931-40.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.